136 results
Page 7 of 7
6-K
EX-99.1
iuzrvc hso8u
27 Feb 19
InflaRx Receives Approval to Initiate Phase IIa Clinical Trial with Lead CandidateIFX-1 in Pyoderma Gangraenosum
8:39am
6-K
EX-99.1
vqu515a3vuj3ch4d3p9n
14 Feb 19
Current report (foreign)
8:44am
6-K
EX-99.1
xq3yxiojy
6 Feb 19
InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:35am
6-K
EX-99.1
lsqgwyxqx1uzzdljpnl
3 Jan 19
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
8:53am
6-K
EX-99.1
8b1twf 44znzq8kk52
19 Dec 18
InflaRx Receives European Approval to Initiate Phase II Clinical Trial with IFX-1 in ANCA-Associated Vasculitis
8:36am
6-K
EX-99.2
be8l0 etpzvhck
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.3
9ydkky0uhf6
21 Nov 18
Current report (foreign)
8:34am
6-K
EX-99.1
t0hcli uu
8 Nov 18
InflaRx Completes Enrollment in Phase IIb Clinical Trial with Lead Candidate IFX-1 in Hidradenitis Suppurativa
8:52am
6-K
EX-99.1
59clrftfvznxf722
30 Oct 18
Current report (foreign)
8:21am
6-K
EX-99.1
xw2g cg0a
21 Sep 18
InflaRx N.V. Announces Appointment of Jens Holstein to Board of Directors
8:38am
6-K
EX-99.2
mceokd
9 Aug 18
Current report (foreign)
7:35am
6-K
EX-99.3
taw3nmzzrm xn02
17 May 18
Current report (foreign)
7:45am
6-K
EX-99.2
v772egq5gknsv7 u9
17 May 18
Current report (foreign)
7:45am
424B4
shr0j2l3c 4g9z5vikl9
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
ylc2ty twjrh
2 May 18
Registration statement (foreign)
7:10am
20-F
4dt0in
29 Mar 18
Annual report (foreign)
12:00am